Evidence-Based Management of Sickle Cell Disease

Expert Panel Report, 2014
# Contents

Foreword ................................................................................................................................. ix

Expert Panel ............................................................................................................................. xi

Chapter 1: Introduction and Methodology ............................................................................. 1
  Historical Perspective, Epidemiology, and Definitions ......................................................... 1
  Overview of the SCD Guidelines Chapters ........................................................................... 2
  Process and Methodology ...................................................................................................... 3
    Evidence Review and Synthesis ......................................................................................... 4
    Literature Search .............................................................................................................. 5
    Evidence Synthesis .......................................................................................................... 5
    Evidence Framework ........................................................................................................ 6
    Determining Evidence Quality ......................................................................................... 6
    Determining the Strength of Recommendations .............................................................. 7
  Existing Systematic Reviews and Clinical Practice Guidelines ........................................... 8
  Consensus Statements ......................................................................................................... 9
    Consensus–Panel Expertise ............................................................................................. 9
    Consensus–Adapted ......................................................................................................... 9
  Clinical Practice Guidelines and the Institute of Medicine .................................................. 10

Chapter 2: Health Maintenance for People With Sickle Cell Disease .................................... 11
  Background ........................................................................................................................ 11
  Methodology ....................................................................................................................... 12
    Prevention of Invasive Pneumococcal Infection ............................................................... 12
      Background .................................................................................................................. 12
      Key Questions ............................................................................................................. 13
      Summary of the Evidence ............................................................................................ 13
      Recommendations ....................................................................................................... 14
    Screening for Renal Disease ........................................................................................... 14
      Background .................................................................................................................. 14
      Key Question ............................................................................................................... 14
      Summary of the Evidence ............................................................................................ 14
      Recommendations ....................................................................................................... 15
    Screening for Pulmonary Hypertension .......................................................................... 15
      Background .................................................................................................................. 15
      Key Question ............................................................................................................... 16
      Summary of the Evidence ............................................................................................ 16
    Electrocardiogram Screening ............................................................................................ 17
      Background .................................................................................................................. 17
      Key Question ............................................................................................................... 17
      Summary of the Evidence ............................................................................................ 17
      Recommendations ....................................................................................................... 17
    Screening for Hypertension ............................................................................................... 18
      Background .................................................................................................................. 18
      Key Questions ............................................................................................................... 18
      Summary of the Evidence ............................................................................................ 18
      Recommendations ....................................................................................................... 19
    Screening for Retinopathy ................................................................................................. 19
      Background .................................................................................................................. 19
      Key Question ............................................................................................................... 19
      Summary of the Evidence ............................................................................................ 19
      Recommendations ....................................................................................................... 20
Chapter 7: Looking Forward ................................................................. 93
New Research Is Needed ................................................................. 93
Data Systems That Meet the Highest Standards of Scientific Rigor Can Be Invaluable
Resources ............................................................... 93
Improved Phenotyping Is Needed ..................................................... 94
Broad Collaborations for Research and Care ....................................... 94
Beyond Efficacy: From Bench to Bedside and the Community .................... 94
Appendixes ...................................................................................... 95
Appendix A. Glossary ......................................................................... 99
Appendix B. PICOS Questions by Chapter ............................................... 109
References ...................................................................................... 113

List of Exhibits

Exhibit 1a. Typical Laboratory Findings in Sickle Cell Disease .................. 2
Exhibit 1b. Typical Laboratory Findings in Sickle Cell Trait (Provided for Comparison) ........... 2
Exhibit 2. Evidence Review Process .................................................... 5
Exhibit 3. Steps in the GRADE Process ................................................ 6
Exhibit 4. GRADE Recommendations—A Closer Look ................................ 7
Exhibit 5. Summary of U.S. Preventive Services Task Force’s General
Recommendations That Are Also Applicable to Persons With Sickle Cell Disease .......... 27
Exhibit 6. Immunization Recommendations as Adapted from the Advisory Committee on Immunization Practices (ACIP) .......... 30
Exhibit 7. Acute Pain Algorithm* ....................................................... 36
Exhibit 8. Stages of Avascular Necrosis ................................................ 59
Exhibit 9. Stages of Kidney Disease by GFR Levels ................................. 64
Exhibit 10. Stages of Proliferative Sickle Retinopathy (PSR) ..................... 68
Exhibit 11. Participant Enrollment Criteria for Placebo-Controlled Randomized
Controlled Trials of Hydroxyurea Therapy in Sickle Cell Disease ................. 74
Exhibit 12. Evidence Profile—Evidence of Efficacy/Effectiveness for Children and Adults With Sickle Cell Anemia (Hydroxyurea Versus Usual Care) .......... 75
Exhibit 13. Evidence Profile—Evidence of Side Effects in Sickle Cell Anemia .......... 75
Exhibit 14. Acute Complications—Graded Recommendations To Transfuse .......... 83
Exhibit 15. Acute Complications—Consensus Recommendations To Transfuse .......... 83
Exhibit 16. Acute Complications—Graded Recommendations When Transfusion Is Not Indicated .................................................. 83
Exhibit 17. Acute Complications—Consensus Recommendations When Transfusion Is Not Indicated .................................................. 84
Exhibit 18. Chronic Complications—Graded Recommendations for When To Initiate a Chronic Transfusion Program .......................... 84
Exhibit 19. Chronic Complications—Graded Recommendations for When Transfusion is Not Indicated .................................................. 84
Exhibit B–1. PICOS Approach for Health Maintenance Chapter: Antibiotics ........... B–109
Exhibit B–2. PICOS Approach for Health Maintenance Chapter: Screening .........................B–109
Exhibit B–3a. PICOS Approach for Health Maintenance Chapter: Blood Pressure
(Question 1).........................................................................................................................B–110
Exhibit B–3b. PICOS Approach for Health Maintenance Chapter: Blood Pressure
(Question 2).........................................................................................................................B–110
Exhibit B–4. PICOS Approach for Acute and Chronic Complications Chapters.........B–110
Exhibit B–5. PICOS Approach for Hydroxyurea Chapter..............................................B–111
Exhibit B–6. PICOS Approach for Transfusion Chapter...............................................B–111
Foreword

The purpose of the “Evidence-Based Management of Sickle Cell Disease: Expert Panel Report (EPR), 2014” is to synthesize the available scientific evidence on sickle cell disease and offer guidance to busy primary care clinicians. Readers of this report should remember that this document is intended to provide guidance for management, not to be rigidly prescriptive. The panel recognizes that the responsible clinician’s judgment regarding the management of patients remains paramount. Therefore, the Expert Panel Report is a tool to be adopted and implemented in local and individual settings, and to provide an opportunity for shared decisionmaking in which providers and patients are both fully engaged.

The EPR has been developed under the outstanding leadership of panel co-chairs Drs. George Buchanan and Barbara Yawn. The production of this report generated much discussion regarding the quality of the available scientific literature, its interpretation, and its practical application. In the end, priority was given to delivering a document that both objectively evaluated and organized the evidence and could be put into practice in the clinical setting, because effective implementation is ultimately what is needed to bring about a change in outcomes.

The NHLBI is grateful for the tremendous dedication of time and the outstanding work of the expert panel, as well as the advice of invited outside experts, the National Blood Disorders Program Coordinating Committee, and other stakeholder groups in developing this report. The invaluable comments from professional societies; voluntary health, government, consumer/patient advocacy organizations; and industry during the public review period greatly enhanced the scientific value and practical utility of this document.

By developing this landmark report, the expert panel has taken a tremendous step towards addressing the health needs of the person with sickle cell disease in the primary care setting. It is incumbent upon the team of health professionals caring for these individuals to change the landscape of care by providing this state-of-the-science care. We are excited to be joined by all concerned in efforts to reach our common ultimate goal: improved health outcomes and quality of life for every person living with sickle cell disease.

Gary H. Gibbons, M.D.
Director
National Heart, Lung, and Blood Institute

Susan B. Shurin, M.D.
Former Deputy Director
National Heart, Lung, and Blood Institute
Expert Panel

Co-Chairs

George R. Buchanan, M.D.
University of Texas Southwestern Medical Center
Dallas, TX

Barbara P. Yawn, M.D., M.Sc., M.S.P.H.
University of Minnesota
Rochester, MN

Members

Araba N. Afenyi-Annan, M.D., M.P.H.
University of North Carolina at Chapel Hill
Chapel Hill, NC

Samir K. Ballas, M.D.
Thomas Jefferson University, Cardeza Foundation
Philadelphia, PA

Kathryn L. Hassell, M.D.
University of Colorado Denver
Aurora, CO

Andra H. James, M.D., M.P.H.
University of Virginia
Charlottesville, VA

Lanetta Jordan, M.D., M.P.H., M.S.P.H.
Foundation for Sickle Cell Disease Research
University of Miami, Miller School of Medicine
Miami, FL

Sophie M. Lanzkron, M.D., M.H.S.
Johns Hopkins School of Medicine
Baltimore, MD

Richard Lottenberg, M.D.
University of Florida
Gainesville, FL

William J. Savage, M.D., Ph.D.
Brigham and Women’s Hospital and Harvard Medical School
Boston, MA

Paula J. Tanabe, Ph.D., R.N., F.A.E.N., F.A.A.N.
Duke University, Schools of Nursing and Medicine
Durham, NC

Russell E. Ware, M.D., Ph.D.
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Methodologist

M. Hassan Murad, M.D., M.P.H.
Mayo Clinic
Rochester, MN

National Heart, Lung, and Blood Institute Staff

Joylene John-Sowah, M.D., M.P.H. (Lead)
Jonathan Goldsmith, M.D., F.A.C.P.
Edward Donnell Ivy, M.D., M.P.H.
Eduardo Ortiz, M.D., M.P.H.
Denise Simons-Morton, M.D., Ph.D.

Contractor Staff

Robinson Fulwood, Ph.D., M.S.P.H., (Kelly Government Services); Ann Horton, M.S.; Mandy David, P.A.-C; Angela Jehle; Susan Bratten; Stephanie Neuben; Marcia Bache, M.M.Sc., RD; Richard Yelle; Yajie Li, M.D., M.S. (American Institutes for Research, Rockville, MD)

---

These individuals contributed to the development of these guidelines during their tenure with the NHLBI Division for the Application of Research Discoveries.

These individuals contributed to the development of these guidelines during their tenure with American Institutes for Research (AIR).
Financial and Other Disclosures

NHLBI established the expert panel and invited the panel members. All members served as volunteers and received no compensation from NHLBI or any other entity for their participation.

During the development of these guidelines, measures were taken to ensure the transparency of the evidence review process and to manage all potential or perceived conflicts of interest. At the initial expert panel meeting, expert panel members were asked by the panel co-chairs to disclose interests and relationships that could potentially influence their participation or pose a potential conflict of interest. The responses are provided below.


Samir K. Ballas, M.D.—Speaker’s Bureau, Novartis; Sickle Cell Advisory Board, HemaQuest; U.S. Sickle Cell Advisory Board, Sangart

Kathryn L. Hassell, M.D.—Advisory Board, ApoPharma; Consultant, AGA Medical Corp.; Consultant and Principal Investigator of Local Site Multicenter Sickle Cell Study, Terumo, Inc.; Principal Investigator of Local Site Multi-Center Sickle Cell Study, GlycoMimetics, Inc.; Principal Investigator of Local Site Multi-Center Sickle Cell Study, Emmaus, Inc.; Board of Directors, Mount Evans Home Health & Hospice; Medical Advisory Board, Foundation for Women and Girls with Blood Disorders; Medical Advisory Board, PFO Research Foundation

Andra H. James, M.D., M.P.H.—Consultancy for the von Willebrand Disease Medical Advisory Board for CSL Behring; Research study of antithrombin levels in pregnancy for Grifols/Talecris; Study of von Willebrand factor levels and fibrinogen levels post partum for CSL Behring; Expert witness for Johnson & Johnson and Sanofi-Aventis

Lanetta Jordan, M.D., M.P.H., M.S.P.H.—National Heart, Lung, and Blood Advisory Council; Faculty Chair, Sickle Cell Disease Association of America, Inc. (SCDAA) and National Initiative for Children’s Healthcare Quality (NICHQ) for Health Resources and Services Administration-funded Sickle Cell Disease Treatment Demonstration Program; AESRx Medical Advisory Council; Prolong Pharmaceutical Medical Advisory Board; Consultant for NKT Therapeutics, TriStem, Pfizer, and Novartis; Board Member, Foundation for Women and Girls with Blood Disorders and Miami YWCA

Sophie M. Lanzkron, M.D., M.H.S.—Scientific Advisory Board for HemaQuest; Principal investigator on studies sponsored by Emmaus, GlycoMimetics, Inc., and Novartis

Paula J. Tanabe, Ph.D., R.N., M.S.N., M.P.H.—Partner, ESI Triage Research Team, LLC; Principal investigator on Agency for Healthcare Research and Quality research grant; Subcontractor to the Michigan Public Health Institute and the Health Resources and Services Administration (HRSA) to conduct a project in SCD, pediatrics, emergency department (ED) research; recipient of Duke School of Nursing grant to complete a project to measure the effect of a high dose opioid protocol to treat adults with a vaso-occlusive crisis (VOC) in the ED; Expert witness consultant on one SCD legal case

Russell E. Ware, M.D., Ph.D.—Consultant for Bayer, Novartis Pharmaceuticals, and Sobi

No relationships to disclose: George R. Buchanan, M.D.; Richard Lottenberg, M.D.; William J. Savage, M.D., Ph.D.; Barbara P. Yawn, M.D., M.Sc., M.S.P.H.
Expert Reviewers

Prior to publication of the final report, the panel sought input from independent expert peer reviewers without financial conflicts of interest. The conclusions and synthesis of the scientific literature presented in this report represent a consensus but do not necessarily represent the views of individual reviewers.

The list of expert peer reviewers follows.

**Ofelia Alvarez, M.D.**
Professor of Clinical Pediatrics
Director, Pediatric Sickle Cell Program
Co-Director, University of Miami Sickle Cell Center
University of Miami Miller School of Medicine
Miami, FL

**Rita Bellevue, M.D.**
Director, Comprehensive Sickle Cell/Thalassemia Program
New York Methodist Hospital
Assistant Professor of Medicine
Weill Cornell Medical College
New York, NY

**David C. Brousseau, M.D., M.S.**
Professor of Pediatrics
Director, Medical School Physician Scientist Pathway
Medical College of Wisconsin
Chief, Section of Pediatric Emergency Medicine
Children’s Hospital of Wisconsin
Milwaukee, WI

**Tiffiny Diers, M.D.**
Assistant Professor of Medicine
University of Cincinnati
Cincinnati, OH

**John Epling, M.D., M.S.Ed., F.A.A.F.P.**
Associate Professor and Chair
Department of Family Medicine
Co-Director, Studying-Acting-Learning-Teaching Network (SALT-Net)
Associate Professor
Public Health and Preventive Medicine
SUNY Upstate Medical University
Syracuse, NY

**Julia C. Finkel, M.D.**
Professor of Anesthesiology and Pediatrics
The George Washington University
Principal Investigator, The Sheikh Zayed Institute for Pediatric Surgical Innovation
Associate Chief and Director of Research
Division of Anesthesiology and Pain Medicine
Children’s National Medical Center
Washington, DC

**Susan K. Jones, R.N.**
Clinical Research Supervisor
UNC Comprehensive Sickle Cell Program
University of North Carolina, Chapel Hill
Chapel Hill, NC

**Rebecca Kruse-Jarres, M.D., M.P.H.**
Associate Professor of Clinical Medicine
Director, Adult Sickle Cell Program
Department of Medicine
Section of Hematology/Oncology
Tulane University
New Orleans, LA

**Abdullah Kutlar, M.D.**
Professor of Medicine
Division of Hematology/Oncology and Stem Cell Transplantation
Director
MCG Sickle Cell Center
Georgia Regents University
Augusta, GA
Annette Lavendar
Nurse Practitioner
Mercy Health Partners
Cincinnati, OH

Brigitta U. Mueller, M.D., M.H.C.M.
Professor of Pediatrics
Baylor College of Medicine
Clinic Chief and Director
Division of Clinical Operations, Quality & Safety
Texas Children’s Cancer and Hematology Centers
Medical Director, Care Management
Texas Children’s Hospital
Houston, TX

Linda Overholser, M.D., M.P.H.
Division of General Internal Medicine
University of Colorado Denver
Denver, CO

Gwendolyn Poles, D.O.
Faculty, IM Residency Program
PinnacleHealth System
Kline Health Center
Harrisburg, PA

Sohail Rana, M.D.
Professor
Department of Pediatric and Child Health
Howard University College of Medicine

Wally R. Smith, M.D.
Professor of Medicine
Virginia Commonwealth University
Richmond, Virginia

John Strouse, M.D.
Assistant Professor of Pediatrics and Medicine
Division of Pediatric Hematology
Department of Pediatrics
Division of Hematology
Department of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Alexis A. Thompson, M.D., M.P.H.
Sarah and A. Watson Armour Chair in Childhood Cancer and Blood Diseases
Hematology Section Head
Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, IL

Knox H. Todd, M.D., M.P.H.
Professor and Chair
Department of Emergency Medicine
MD Anderson Cancer Center
Houston, TX

Special thanks to the American Academy of Pediatrics for their ongoing collaboration and review.
Expert Panel Report Endorsements

Academy of Emergency Medicine (AAEM)
American Academy of Pediatrics (AAP)
American Academy of Physician Assistants (AAPA)
American Osteopathic Association (AOA)
American Society of Hematology (ASH)
American Society of Pediatric Hematology/Oncology (ASPHO)
International Association of Sickle Cell Nurses and Physician Assistants (IASCNAPA)
National Black Nurses Association (NBNA)
National Initiative for Children’s Health Quality (NICHQ)
National Medical Association (NMA)
Sickle Cell Disease Association of America (SCDA})